Oestrogen Withdrawal in Hypopituitary Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-01-31

Study Completion Date

2002-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

By exploring hormonal status in hypopituitary women during oestrogen treatment and without estrogen substitution the influence on sexhormones and organ function is estimated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

38 hypopituitary women were examinined twice. During oestrogen treatment and after 1 month estrogen withdrawal. A control group of healthy women were examined once.Antropometric data and hormonal parameters were collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypopituitarism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

No oestrogen treatment

Group Type PLACEBO_COMPARATOR

oestrogen

Intervention Type DRUG

Cyclic oestrogen substitution therapy

2

Oestrogen treatment

Group Type EXPERIMENTAL

oestrogen

Intervention Type DRUG

Cyclic oestrogen substitution therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oestrogen

Cyclic oestrogen substitution therapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypopituitarism

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Århus universityhospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jens J Christiansen, PhD

Role: PRINCIPAL_INVESTIGATOR

Århus Universityhospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Århus Universityhospital

Aarhus, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Host C, Christiansen JJ, Christiansen JS, Jorgensen JO, Gravholt CH. Discontinuation of hormone replacement therapy in young GH-treated hypopituitary women increases liver enzymes. Growth Horm IGF Res. 2010 Feb;20(1):26-30. doi: 10.1016/j.ghir.2009.07.001. Epub 2009 Aug 5.

Reference Type DERIVED

PMID: 19660970 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1999/4644

Identifier Type: -

Identifier Source: secondary_id